PURPOSE: Breast cancer is a significant public health issue worldwide, with a particularly high impact in Latin America (LATAM). Genetic risk assessment and germline molecular testing for pathogenic variants in actionable genes are established practices for managing breast cancer risk. Cascade testing, genetic testing of at-risk relatives of individuals carrying these variants, provides a pivotal strategy for cancer prevention and early detection. DESIGN: This review examines the status of cascade testing among patients with breast cancer in LATAM, highlighting the barriers to its implementation and identifying opportunities to expand its application in the region. RESULTS: Despite growing awareness of the importance of genetic risk assessment, the adoption of cascade testing remains limited in LATAM. Key barriers include restricted access to genetic services, financial and infrastructural limitations within public health systems, and sociocultural factors. However, locally driven initiatives that integrate genetic counseling into national health systems and emphasize education for health care providers have demonstrated the potential to foster long-term sustainability. The role of artificial intelligence and machine learning in genetic counseling is emerging, offering possible solutions to optimize cascade testing, but further evidence is required to assess their impact across diverse populations. CONCLUSION: The successful integration of cascade testing into Latin American health care systems requires strategies rooted in local initiatives, supported by public policies, and driven by health care professionals committed to changing paradigms in cancer prevention. Sustainable approaches should prioritize capacity-building, equitable access to genetic services, and the empowerment of health care providers to recognize the transformative impact of genetic counseling on patient outcomes. By fostering regionally adapted models, LATAM can enhance hereditary cancer prevention and ultimately reduce breast cancer incidence and mortality.
1 May 2026 in Journal of Comparative Effectiveness Research
Aim: The availability of subcutaneous (SC) trastuzumab has introduced a practical alternative to traditional intravenous (IV) delivery for HER2-positive breast cancer. Beyond clinical equivalence, the shift toward SC administration offers the possibility of reorganizing workflow, reducing the pressure on infusion units and improving the treatment experience for both patients and healthcare professionals. This study provides real-world evidence from a large public oncology hospital in Mexico City, examining how SC and IV trastuzumab compare in everyday practice with respect to treatment times, resources use and the perceptions of patients and staff. Materials & methods: A prospective time and motion study was conducted to compare the efficiency and operational impact of SC and IV routes of trastuzumab administered as monotherapy in women with HER2-positive breast cancer at a public hospital in Mexico City. Sixty administrations (30 SC and 30 IV) were analyzed, recorded in real time using a digital system specifically developed for this study. The system documented waiting times, preparation, administration and time spent in the treatment room. Resource utilization was estimated based on the average number of supplies required for each route. In addition, patients and healthcare personnel completed structured questionnaires on comfort, satisfaction and overall experience. Results: Treatment using the SC route was noticeably shorter. Compared with the IV route, median chair time and overall procedure duration dropped by close to 94%, and treatment room occupancy decreased by approximately 83%. This route also required fewer materials and avoided the drug loss due to weight-based IV dosing. Patients described the SC injection as more comfortable and less fatiguing, while healthcare professionals noted less physical effort, lower stress levels and a more manageable workflow. Conclusion: In a routine public oncology setting with limited resources, the use of SC trastuzumab was associated with clear advantages in terms of efficiency and the treatment experience while also mitigating the workload of infusion areas. These results provide practical, context-specific evidence that could help healthcare systems to improve the organization of oncology services and make better use of scarce hospital resources.
Cancer diagnosis has been described as a significant factor causing psychological stress, which may increase a vulnerability to develop psychological disorders, decrease quality of life levels and affect the response to cancer treatment. To validate the Newly Diagnosed Breast Cancer Stress Scale (NDBCSS) and to explore the differences concerning clinical and sociodemographic variables. Cross-sectional study. Patients recently diagnosed with breast cancer on the day they received the definitive cancer diagnosis were invited to participate. The Perceived Stress Scale (PSS) and the NDBCSS were completed; the latter previously underwent a validation process into Spanish (reliability, content validity, structure -EFA- and convergent validity). 176 patients participated; their mean age was of 52.8 years. The scale obtained a content validity of 0.53 and reliability of 0.791; the EFA showed 2 factors explaining 42.31% of the variance. Stress levels were 23.05 (PSS) and 13.2 (NDBCSS). Concern about side effects, the progression of the illness and the lack of information were reported as the most critical stressors for these patients. The NDBCSS showed acceptable psychometric properties for its application in Mexican patients and probably for patients with similar personal characteristics and linguistic and cultural contexts. Based on the results, it is possible to design precise interventions addressed to the stressors they face, such as the impact of the disease and the treatment.
IMpassion130 trial results led to approval of first-line atezolizumab plus nab-paclitaxel for PD-L1-positive advanced triple-negative breast cancer (aTNBC). The global single-arm EL1SSAR study (NCT04148911) enrolled a broader patient population to elucidate outcomes in routine practice. Patients with measurable PD-L1-positive aTNBC and no prior systemic therapy for advanced disease received atezolizumab (840 mg, days 1&15) plus nab-paclitaxel (100 mg/m2, days 1,8,15) every 28 days until disease progression or unacceptable toxicity. PD-L1 status was assessed locally (mandatory) and centrally (optional) using the VENTANA PD-L1 (SP142) Assay. Patients with stable asymptomatic CNS metastases, ECOG PS 2 or selected autoimmune diseases were allowed. Primary endpoints were the incidence of grade ≥2 immune-mediated and grade ≥3 adverse events (AEs). Secondary endpoints included overall survival and investigator-assessed progression-free survival (PFS). PD-L1 testing concordance was an exploratory endpoint. Among 182 treated patients, five had CNS metastases and three had ECOG PS ≥ 2. Patients received a median of six treatment cycles (range 1-63); 7% were treated for >3 years. Grade ≥2 immune-mediated AEs occurred in 12% of patients (95% CI 8%-18%) and grade ≥3 AEs in 47% (95% CI 39%-54%). There were no treatment-related deaths. Median PFS was 7.4 (95% CI 5.6-10.6) months (>2 years in 27 patients [15%]) and median overall survival was 27.0 (95% CI 22.0-33.8) months. Concordance between local and central PD-L1 testing was 67% (65/97). Median PFS was >11 months in patients with centrally confirmed PD-L1-positive status. Safety and efficacy were consistent with results from IMpassion130, which enrolled a more selected population.